Myelodysplastic syndromes: moving towards personalized management.

ABSTRACT: The myelodysplastic syndromes (MDS) share their origin in the hematopoietic stem cell but have otherwise very heterogeneous biological and genetic characteristics. Clinical features are dominated by cytopenia and a substantial risk for progression to acute myeloid leukemia. According to the World Health Organization, MDS is defined by cytopenia, bone marrow dysplasia and certain karyotypic abnormalities. The understanding of disease pathogenesis has undergone major development with the implementation of next-generation sequencing and a closer integration of morphology, cytogenetics and molecular genetics is currently paving the way for improved classification and prognostication. True precision medicine is still in the future for MDS and the development of novel therapeutic compounds with

SUBMITTER: Hellstrom-Lindberg E 

PROVIDER: S-EPMC7327628 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature